Clinical Trials Logo

Clinical Trial Summary

Studies objectives: To evaluate the safety, tolerability and efficacy of ACC given in combination with ZA or with Denosumab as compared to placebo given with ZA or with Denosumab as outline below: - Safety and Tolerability: - Adverse events (AEs) and serious AEs - Safety laboratory measurements - Hypercalcemic and hypercalciuric episodes - Treatment withdrawal due to AEs and overall Efficacy: - Skeletal Related Events (SREs) - Measurable and evaluable disease progression - Progression Free Survival (PFS) - Pain assessment via the VAS scale


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02864784
Study type Interventional
Source Amorphical Ltd.
Contact
Status Withdrawn
Phase Phase 1
Start date June 2022
Completion date December 2023